Business Context and Reporting Period
This Form 8-K filing by AnaptysBio, Inc. (Nasdaq: ANAB) reports on the results of the 2022 Annual Meeting of Stockholders held on June 23, 2022. The filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance report regarding stockholder votes and does not contain financial performance data.
Material Changes and Voting Results
The following proposals were adopted by stockholders at the Annual Meeting:
- Election of Directors: Three Class II directors were elected to three-year terms expiring at the 2025 Annual Meeting:
- Laura J. Hamill (18,530,964 shares For)
- James Topper, M.D., Ph.D. (18,338,960 shares For)
- J. Anthony Ware, M.D. (18,397,904 shares For)
- Ratification of Auditors: KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2022 (25,369,483 shares For vs. 30,540 shares Against).
- Executive Compensation: Non-binding advisory approval of executive compensation was granted (21,241,128 shares For vs. 1,166,695 shares Against).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the reporting of voting outcomes.
Key Facts for Investor Verification
- Verify the tenure of the newly elected directors (Laura J. Hamill, James Topper, and J. Anthony Ware) through the 2025 Annual Meeting.
- Confirm the appointment of KPMG LLP as the auditor for the fiscal year ending December 31, 2022.
- Note the significant number of broker non-votes (2,986,393) recorded for the director elections and executive compensation proposal.
- Review the company's most recent 10-K or 10-Q filings for financial metrics, as this 8-K contains no financial data.